

해외 바이오의약품 임상 현황 ('23년 5월 5주)

한국바이오의약품협회, 2023.06.07.

※ ClinicalTrials.gov에 등록된 국가별 바이오의약품 임상시험 목록(병용요법 포함)을 한국바이오의약품협회에서 주간 업데이트하여 제공합니다.

URL을 클릭하시면 세부 정보 페이지로 연결됩니다.

- 출처: ClinicalTrials.gov
- 모니터링 기간: 2023.05.29.~2023.06.04.
- 주간 업데이트 제공국가 : 미국, 유럽(영국, 프랑스, 독일), 중국, 일본

○ 미국 87건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05878951	Examining the Effects of Intra-detrusor Botulinum Toxin at Time of Holmium Laser Enucleation of the Prostate (HoLEP) in Men With Overactive Bladder (OAB) Symptoms	Drug: OnabotulinumtoxinA	Northwestern University University of Calgary Ohio State University University of Alberta	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05878951
NCT05859490	Immunogenicity of Yellow Fever Vaccine 17D in Adults With Prior 17D Vaccination	Biological: 17D	Oregon Health and Science University	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05859490
NCT04691817	Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy	Drug: Atezolizumab Drug: Tocilizumab	Abramson Cancer Center at Penn Medicine Genentech, Inc.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04691817
NCT02522611	Periganglionic Resiniferatoxin for the Treatment of Intractable Pain Due to Cancer-induced Bone Pain	Drug: Resiniferatoxin	National Institute of Neurological Disorders and Stroke (NINDS) National Institutes of Health Clinical Center (CC)	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT02522611
NCT05769959	Study of RO7515629 in Participants With HLA-G Positive Solid Tumors	Drug: RO7515629 Drug: tocilizumab	Hoffmann-La Roche	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05769959
NCT05625633	Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts	Biological: Human Papillomavirus 9-valent Vaccine, Recombinant Other: Normal Saline	Western Institute for Veterans Research University of Utah Merck Sharp & Dohme LLC	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05625633
NCT05407441	Tazemetostat+Nivo/Ipi in IN1-Neg/SMARCA4-Def Tumors	Drug: Tazemetostat Drug: Nivolumab Drug: Ipilimumab	Susan Chi, MD Bristol-Myers Squibb Epizyme, Inc. Dana-Farber Cancer Institute	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05407441
NCT04774536	Transplantation of Clustered Regularly Interspaced Short Palindromic Repeats Modified Hematopoietic Progenitor Stem Cells (CRISPR_SCD001) in Patients With Severe Sickle Cell Disease	Drug: CRISPR_SCD001	Mark Walters, MD University of California, Los Angeles University of California, Berkeley University of California, San Francisco	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04774536
NCT05873712	Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome	Procedure: Biospecimen Collection Procedure: Bone Marrow Biopsy Procedure: Computed Tomography Drug: Cyclophosphamide Drug: Fludarabine Procedure: Leukapheresis Biological: Lisocabtagene Maraleucel Procedure: Lymph Node Biopsy Procedure: Positron Emission Tomography Drug: Zanubrutinib	Adam Kittai Ohio State University Comprehensive Cancer Center	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05873712
NCT05854966	CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)	Drug: CPI 613 Drug: Metformin Biological: Blood draws Procedure: Bone marrow biopsy	Wake Forest University Health Sciences National Cancer Institute (NCI) Cornerstone Pharmaceuticals	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05854966

해외 바이오의약품 임상 현황 ('23년 5월 5주)

한국바이오의약품협회, 2023.06.07.

○ 미국 87건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05852574	CP101 for the Treatment of Ulcerative Colitis	Drug: CP-101 Drug: CP-101 + Placebo	Brigham and Women's Hospital	Phase 1	
NCT05847569	Alternate Doses and Dosing Schedules of Belantamab Mafodotin for the Treatment of Triple-Class Recurrent and/or Refractory Multiple Myeloma	Biological: Belantamab Mafodotin Procedure: Biospecimen Collection Procedure: Bone Marrow Aspirate Procedure: Bone Marrow Biopsy Procedure: Computed Tomography Procedure: Magnetic Resonance Imaging Procedure: Positron Emission Tomography	Mayo Clinic	Phase 2	
NCT05843448	IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer	Biological: PD-L1/IDO Peptide Vaccine Biological: Pembrolizumab	Mamta Parikh IO Biotech National Cancer Institute (NCI) University of California, Davis	Phase 1	
NCT05838092	Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)	Drug: allo-APZ2-OTS Drug: Placebo	RHEACELL GmbH & Co. KG	Phase 3	
NCT05833867	Adaptive RADIation Therapy With Concurrent Sacituzumab Govitecan (SG) for Muscle Invasive Bladder Cancer	Drug: Sacituzumab govitecan Radiation: Adaptive Radiotherapy	Omar Mian Varian Inc Gilead Sciences Case Comprehensive Cancer Center	Phase 1	
NCT05829239	ADI-PEG20, Obesity and Prediabetes	Biological: ADI-PEG20 Other: Placebo	Washington University School of Medicine Children's Discovery Institute Polaris Pharmaceuticals, Inc.	Phase 2	
NCT05820711	Study Transplanting Bone Marrow Cells Into Salivary Glands to Treat Dry Mouth Caused by Radiation Therapy	Drug: MSC	University of Wisconsin, Madison National Institute of Dental and Craniofacial Research (NIDCR)	Phase 1	
NCT05819138	Type 1 Diabetes Impacts of Semaglutide on Cardiovascular Outcomes	Drug: Semaglutide Pen Injector Drug: Placebo	University of Colorado, Denver National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	
NCT05814627	Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis	Drug: Upadacitinib Drug: Adalimumab Drug: Upadacitinib Matching Placebo Drug: Adalimumab Matching Placebo	AbbVie	Phase 3	
NCT05812924	A Novel Therapy for Breast Cancer Survivors With Genitourinary Syndrome of Menopause	Biological: Platelet-rich plasma (PRP)	University of Miami	Phase 2	
NCT05806814	Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer	Biological: Sipuleucel-T	University of Oklahoma Dendreon	Phase 1	

해외 바이오의약품 임상 현황 ('23년 5월 5주)

한국바이오의약품협회, 2023.06.07.

○ 미국 87건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05799144	pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer	Biological: DNA Vaccine Biological: Human Papillomavirus Tumor Antigen Vaccine Biological: Pembrolizumab Procedure: Computed Tomography (CT) Procedure: Magnetic Resonance Imaging (MRI) Procedure: Magnetic Resonance Imaging Procedure: Biopsy	Michael K. Gibson Vanderbilt-Ingram Cancer Center	Phase 2	
NCT05779423	Cryoablation+Ipilimumab+Nivolumab in Melanoma	Drug: Ipilimumab Drug: Nivolumab Procedure: Cryoablation	Massachusetts General Hospital William M. Wood Foundation	Phase 2	
NCT05747625	(89Zr Panitumumab) With PET/CT for Diagnosing Metastases in Patients With Head and Neck Squamous Cell Carcinoma	Biological: Panitumumab Drug: Zirconium Zr 89 Panitumumab Procedure: Positron Emission Tomography Procedure: Computed Tomography Other: Electronic Health Record Review	Michael Topf Vanderbilt-Ingram Cancer Center	Phase 1	
NCT05729139	Cemiplimab/Peg-Interferon-α in Advanced CSCC	Drug: Cemiplimab-Rwlc Drug: PEG-IFN alfa-2a	Baptist Health South Florida Regeneron Pharmaceuticals	Phase 1	
NCT05724563	Domvanalimab and Zimberelimab in Advanced Liver Cancers	Drug: Zimberelimab Drug: Domvanalimab	University of Texas Southwestern Medical Center Arcus Biosciences, Inc. Cancer Prevention Research Institute of Texas	Phase 2	
NCT05724134	Pancreatic Clamp in NAFLD	Drug: Insulin human Drug: Octreotide Acetate Drug: Glucagon Drug: Growth Hormone, Human Other: [6,6-2H2] D-glucose Drug: 20% D-glucose (aq) Dietary Supplement: BOOST Plus Device: Harvard Apparatus PHD ULTRA CP syringe pump Device: Yellow Springs Instruments (YSI) 2500 Biochemistry Glucose/Lactate Analyzer	Columbia University Albert Einstein College of Medicine	Phase 1	
NCT05717140	Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung	Biological: Aerosol Sargramostim Procedure: Biospecimen Collection Procedure: Computed Tomography Procedure: Magnetic Resonance Imaging Other: Medical Device Usage and Evaluation Biological: Nivolumab	Mayo Clinic	Phase 2	
NCT05707702	Lactobacillus Lozenges as Preventative Care in Low-grade Dysplasia	Biological: Probiotic oral lozenges Other: Standard of care for oral dysplasia	Boston Medical Center University of Alabama at Birmingham	Phase 3	
NCT05669833	Guselkumab vs Golimumab in PSA TNF Inadequate Responder Patients	Drug: Guselkumab Drug: Golimumab Drug: Placebo	University of Pennsylvania Janssen Scientific Affairs, LLC	Phase 3	
NCT05663710	Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC	Drug: 177Lu girentuximab Drug: Nivolumab Drug: Cabozantinib Drug: ArabinoFuranosylGuanine [18F]F-AraG	M.D. Anderson Cancer Center Telix Pharmaceuticals Limited	Phase 2	

해외 바이오의약품 임상 현황 ('23년 5월 5주)

한국바이오의약품협회, 2023.06.07.

○ 미국 87건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05627479	MAGIK for Femoral/Tibial Shaft Fractures	Drug: GIK solution Drug: Isotonic Normal Saline Solution	NYU Langone Health	Phase 2	
NCT05621668	A First-In-Human Phase 1 Trial of T-Cell Membrane-Anchored Tumor Targeted IL12 (AttIL2)- T-Cell Therapy in Subjects With Advanced/Metastatic Soft Tissue and Bone Sarcoma	Drug: Cyclophosphamide Drug: attIL2-T cells	M.D. Anderson Cancer Center	Phase 1	
NCT05567770	ACTinium-J591 Radionuclide Therapy in PSMA-Detected Metastatic Hormone-Sensitive Recurrent Prostate CaNcer	Drug: Actinium-J591 Radiation: Stereotactic Body Radiation Therapy Drug: Androgen Deprivation Therapy	Weill Medical College of Cornell University Convergent Therapeutics, Inc.	Phase 1	
NCT05561387	Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment	Drug: Bortezomib Drug: Daratumumab and Hyaluronidase-fihj Drug: Dexamethasone Drug: Lenalidomide Other: Quality-of-Life Assessment Other: Questionnaire Administration	SWOG Cancer Research Network National Cancer Institute (NCI)	Phase 3	
NCT05498220	Polatuzumab Vedotin With R-GDP in Relapsed/Refractory Diffuse Large B-cell Lymphoma	Drug: Polatuzumab vedotin (PV) Drug: Rituximab Drug: Hyaluronidase Drug: Gemcitabine Drug: Cisplatin Drug: Dexamethasone Drug: GCSF	UNC Lineberger Comprehensive Cancer Center Genentech, Inc.	Phase 2	
NCT05478837	Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma	Drug: Cyclophosphamide Drug: Fludarabine Biological: Autologous Anti-H3.3K27M TCR-expressing T-cells	University of California, San Francisco The V Foundation Parker Institute for Cancer Immunotherapy Alliance for Cancer Gene Therapy	Phase 1	
NCT05457959	Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant	Biological: Dendritic Cell Tumor Peptide Vaccine Biological: Ipilimumab Procedure: Leukapheresis Biological: Nivolumab Drug: Placebo Administration Drug: Poly ICLC Procedure: Resection	Jonsson Comprehensive Cancer Center	Phase 1	
NCT05425576	OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition	Drug: OT-101	Oncotelic Inc. Mateon Therapeutics	Phase 2	
NCT05283109	ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM	Biological: Tumor Associated Antigen Peptide Vaccine P30-EPS Vaccine Drug: Hiltonol	Mustafa Khasraw, MBChB, MD, FRCP, FRACP National Cancer Institute (NCI) Duke University	Phase 1	
NCT05187182	CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer	Drug: CA-4948 Biological: Nivolumab Biological: Pembrolizumab Drug: Trastuzumab Drug: mFOLFOX7	Washington University School of Medicine Curis, Inc. The Foundation for Barnes-Jewish Hospital	Phase 1	
NCT05171062	Dose Escalation Trial of Bexmarilimab (FP-1305) Plus Pembrolizumab in Non-Small Cell Lung Cancer	Drug: bexmarilimab (FP-1305) Drug: Pembrolizumab	The University of Texas Health Science Center at San Antonio Faron Pharmaceuticals Ltd	Phase 1	
NCT05127824	Autologous Dendritic Cell Vaccine in Kidney Cancer	Biological: Autologous alpha-DC1/TBVA vaccine Drug: Cabozantinib	Jodi Maranchie University of Pittsburgh	Phase 2	

해외 바이오의약품 임상 현황 ('23년 5월 5주)

한국바이오의약품협회, 2023.06.07.

○ 미국 87건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05054790	Augmentation Cystoplasty Using an Autologous Neo-Bladder Construct	Biological: "Neo-Bladder" Construct	Wake Forest University Health Sciences	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05054790
NCT05010564	CAR-T Cell, B-cell Acute Lymphoblastic Leukemia (TriCAR)	Genetic: Autologous TriCAR T-cells and lymphodepletion chemotherapy	Baylor College of Medicine Texas Children's Cancer Center	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05010564
NCT04881240	Study of CD19-directed Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia	Biological: CD19-CAR(Mem) T-cells Drug: Cyclophosphamide Drug: Fludarabine Drug: Mesna Device: CliniMACS Procedure: Leukapheresis	St. Jude Children's Research Hospital	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT04881240
NCT04808505	A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglusosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18	Biological: Cipaglusosidase alfa Drug: Miglustat	Amicus Therapeutics	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT04808505
NCT04569461	Trimodality Approach of Low Dose iOnizing Radiation With or Without Neoadjuvant Pembrolizumab and Prostatectomy for Men With Intermediate/High Risk Prostate Cancer (TALON)	Drug: pembrolizumab Radiation: Stereotactic body radiation therapy Drug: Short-term androgen deprivation therapy Procedure: Radical Prostatectomy	Daniel George, MD Merck Sharp & Dohme LLC Duke University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04569461
NCT04220008	Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma	Procedure: Allogeneic Hematopoietic Stem Cell Transplantation Drug: Busulfan Drug: Clofarabine Drug: Cyclophosphamide Drug: Gemcitabine Drug: Mycophenolate Mofetil Biological: Rituximab Drug: Tacrolimus Drug: Vorinostat	M.D. Anderson Cancer Center National Cancer Institute (NCI)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04220008
NCT04093323	Polarized Dendritic Cell (aDC1) Vaccine, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma	Biological: Alpha-type-1 Polarized Dendritic Cells Drug: Celecoxib Drug: PD-1 Ligand Inhibitor Drug: PD1 Inhibitor Biological: Recombinant Interferon Alfa-2b Drug: Rintatolimod	Roswell Park Cancer Institute National Cancer Institute (NCI)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04093323
NCT03939585	Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT	Biological: Cellular therapy product	Leland Metheny Case Comprehensive Cancer Center	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT03939585
NCT05885412	A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)	Genetic: RP-A601	Rocket Pharmaceuticals Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05885412
NCT05856890	HepB mAb19 in Chronic Hepatitis B	Biological: HepB mAb19 Other: Sterile Saline	Rockefeller University NYU Langone Health	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05856890
NCT05826275	Phase 1 Trial in Patients With Human Papillomavirus (HPV)-Associated Cancer	Drug: TGN-S11 Drug: Pembrolizumab	Toragen, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05826275

해외 바이오의약품 임상 현황 ('23년 5월 5주)

한국바이오의약품협회, 2023.06.07.

○ 미국 87건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05795101	TRUDI: TDXD+Durva in HER2+/Low IBC	Drug: Trastuzumab deruxtecan Drug: Durvalumab	Filipa Lynce, MD AstraZeneca Daiichi Sankyo, Inc. Dana-Farber Cancer Institute	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05795101
NCT05656235	Renal Retention in High Grade Upper Tract Urothelial Cancer	Drug: Enfortumab vedotin Drug: Pembrolizumab	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Astellas Pharma Inc Seagen Inc Merck Sharp & Dohme LLC	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05656235
NCT05504837	A Study Assessing KB407 for the Treatment of Cystic Fibrosis	Biological: KB407 (Nebulization)	Krystal Biotech, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05504837
NCT05864144	A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors	Drug: SNS-101 (anti-VISTA) Drug: Cemiplimab	Sensei Biotherapeutics, Inc. Regeneron Pharmaceuticals	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05864144
NCT05498389	EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer	Drug: EMB-01 Drug: Osimertinib	Shanghai EpimAb Biotherapeutics Co., Ltd. Labcorp Corporation of America Holdings, Inc	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05498389
NCT05859464	A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors	Drug: ZL-1218 Drug: Pembrolizumab	Zai Lab (Hong Kong), Ltd. Zai Biopharmaceutical (Suzhou) Co., Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05859464
NCT05846789	Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers	Drug: Carboplatin Drug: Tocilizumab	Kathy Miller Genentech, Inc. Indiana University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05846789
NCT05844228	A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218	Drug: VIR-2218	Vir Biotechnology, Inc.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05844228
NCT05774184	A Study of CDX-0159 in Patients With Eosinophilic Esophagitis	Biological: barzolvolimab Drug: Matching Placebo	Celldex Therapeutics	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05774184
NCT05715229	Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy	Drug: Nivolumab Drug: Ipilimumab Drug: Carboplatin Drug: Paclitaxel Drug: Pemetrexed	Hackensack Meridian Health MedSIR	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05715229
NCT05376319	PR3-AAV Resilient Remission or PRRR	Drug: Obinutuzumab Drug: Rituximab	Mayo Clinic	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05376319
NCT05176288	Avelumab, Palbociclib and Axitinib in Advanced RCC	Drug: Axitinib Drug: Palbociclib Drug: Avelumab	Bradley A. McGregor, MD Pfizer Dana-Farber Cancer Institute	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05176288

해외 바이오의약품 임상 현황 ('23년 5월 5주)

한국바이오의약품협회, 2023.06.07.

○ 미국 87건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05764239	Efficacy and Safety of SYN816 in Patients With PKU (SYNPHENY-3)	Drug: SYN816v1 Drug: Placebo	Synlogic	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05764239
NCT05365659	IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas	Drug: IKS03	Iksuda Therapeutics Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05365659
NCT05879744	A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)	Drug: CLN-978	Cullinan Oncology, LLC	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05879744
NCT05874193	A Collaborative Community Effort Using Belantamab Mafodotin in Relapsed/Refractory Myeloma	Drug: Belantamab mafodotin	Cristiana Costa Chase, DO Duke University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05874193
NCT05469802	A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults	Biological: Purified Inactivated Zika Virus Vaccine (PIZV) Other: Placebo	Takeda	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05469802
NCT05419518	Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas	Biological: EXTERNAL BEAM RADIATION	Rutgers, The State University of New Jersey	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05419518
NCT05194293	Neoadjuvant Regorafenib Plus Durvalumab (MEDI4736) in Patients With High-risk Hepatocellular Carcinoma	Biological: Durvalumab Drug: Regorafenib	Academic and Community Cancer Research United National Cancer Institute (NCI)	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05194293
NCT05854381	To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV	Biological: VIR-1388 Biological: Placebo	Vir Biotechnology, Inc. National Institute of Allergy and Infectious Diseases (NIAID) HIV Vaccine Trials Network	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05854381
NCT05836012	Safety and Immunogenicity of HIL-214 With Routine Pediatric Vaccines	Biological: HIL-214 Biological: Placebo	HilleVax	Phase 2 Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05836012
NCT05874713	Study to Evaluate Safety and Immunogenicity of Different Priming and Booster Regimens With Adjuvanted H5N8 and/or H5N6 Influenza Vaccine in Adults	Biological: aH5N8c on Day 1 Biological: aH5N6c on Day 1 Biological: aH5N8c on Day 22 Biological: aH5N6c on Day 22 Biological: aH5N8c on Day 202	Seqirus Department of Health and Human Services	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05874713
NCT05733611	RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC	Biological: RP2 Biological: RP3 Biological: atezolizumab Biological: bevacizumab	Replimune Inc. Roche Pharma AG	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05733611
NCT05638581	Trauma Resuscitation With Low-Titer Group O Whole Blood or Products	Biological: LTOWB Biological: Components	University of Alabama at Birmingham National Heart, Lung, and Blood Institute (NHLBI) The University of Texas Health Science Center, Houston	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05638581

해외 바이오의약품 임상 현황 ('23년 5월 5주)

한국바이오의약품협회, 2023.06.07.

○ 미국 87건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05873205	Open-Label, Phase II Trial of Isatuximab for Patients With Refractory Immune Cytopenias After Allogeneic Hematopoietic Cell Transplantation	Biological: Isatuximab	Memorial Sloan Kettering Cancer Center Sanofi	Phase 2	
NCT05868265	A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract	Drug: Enfortumab Vedotin Procedure: Radical surgery	Memorial Sloan Kettering Cancer Center Astellas Pharma US, Inc.	Phase 2	
NCT05836259	Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM	Genetic: TN-201	Tenaya Therapeutics	Phase 1	
NCT05733598	RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC	Biological: RP3 Biological: atezolizumab Biological: bevacizumab	Replimune Inc. Roche Pharma AG	Phase 2	
NCT05875961	Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults	Biological: Low dose A/H2N3c + standard dose MF59 Biological: Intermediate dose A/H2N3c + standard dose MF59 Biological: High dose A/H2N3c + standard dose MF59 Biological: High dose A/H2N3c non-adjuvanted Biological: Lowest dose A/H2N3c + high dose MF59 Biological: Low dose A/H2N3c + high dose MF59	Seqirus Department of Health and Human Services	Phase 1	
NCT05888831	A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors	Drug: BMS-986449 Drug: Nivolumab	Bristol-Myers Squibb	Phase 1 Phase 2	

○ 영국 7건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05665166	Autologous Ex-vivo Gene Modified HSCT in MPSII	Genetic: Autologous CD34+ HSCs transduced ex vivo with CD11B LV encoding human IDS tagged with ApoEII	University of Manchester AVROBIO CTI Clinical Trial and Consulting Services Great Ormond Street Hospital for Children NHS Foundation Trust Manchester University NHS Foundation Trust	Phase 1 Phase 2	
NCT05208242	Strong Albumin Solutions in Patients With Septic Shock	Drug: hyperoncotic human albumin solution Drug: Buffered crystalloid solutions	Manchester University NHS Foundation Trust University of Manchester	Phase 2 Phase 3	
NCT05848765	Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy	Drug: Epcoritamab Drug: Lenalidomide Drug: Rituximab Drug: Obinutuzumab Drug: Bendamustine Drug: Vincristine Drug: Doxorubicin Drug: Cyclophosphamide Drug: Prednisone Drug: Investigation agent 2 Drug: Investigation agent 3	University of Birmingham Cancer Research UK Genmab	Phase 2	
NCT05817812	A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥ 2 Years Treated Once Weekly With Efanesoctocog Alfa	Drug: Efanesoctocog alfa	Swedish Orphan Biovitrum Syneos Health	Phase 3	

해외 바이오의약품 임상 현황 ('23년 5월 5주)

한국바이오의약품협회, 2023.06.07.

○ 영국 7건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05615818	Personalized Medicine for Advanced Biliary Cancer Patients	Drug: Futibatinib Drug: Ivosidenib Drug: Zanidatamab Drug: Trastuzumab Drug: Neratinib Drug: Encorafenib Drug: Binimetinib Drug: Niraparib Drug: Cisplatin Drug: Gemcitabine	UNICANCER Cancer Research UK & UCL Cancer Trials Centre Belgian Group of Digestive Oncology National Cancer Institute, France Cancer Research UK Taiho Oncology, Inc. Servier Zymeworks Inc. Accord Healthcare, Inc. Pierre Fabre Medicament GlaxoSmithKline Research & Development Limited	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05615818
NCT05733598	RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC	Biological: RP3 Biological: atezolizumab Biological: bevacizumab	Replimune Inc. Roche Pharma AG	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05733598
NCT05733611	RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC	Biological: RP2 Biological: RP3 Biological: atezolizumab Biological: bevacizumab	Replimune Inc. Roche Pharma AG	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05733611

○ 프랑스 8건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05622071	Testing Immunotherapy for Patients With Liver Cancer and Moderately Altered Liver Functions	Drug: Tislelizumab	UNICANCER	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05622071
NCT02866565	Assessment of the Efficacy and Tolerance of Sub-cutaneous Re-injection of Autologous Adipose-derived REGenerative Cells in the Local Treatment of Neuropathic Diabetic Foot ulcers	Drug: adipose-derived regenerative cells (ADRCs)	Assistance Publique Hopitaux De Marseille	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT02866565
NCT05888831	A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors	Drug: BMS-986449 Drug: Nivolumab	Bristol-Myers Squibb	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05888831
NCT05615818	Personalized Medicine for Advanced Biliary Cancer Patients	Drug: Futibatinib Drug: Ivosidenib Drug: Zanidatamab Drug: Trastuzumab Drug: Neratinib Drug: Encorafenib Drug: Binimetinib Drug: Niraparib Drug: Cisplatin Drug: Gemcitabine	UNICANCER Cancer Research UK & UCL Cancer Trials Centre Belgian Group of Digestive Oncology National Cancer Institute, France Cancer Research UK Taiho Oncology, Inc. Servier Zymeworks Inc. Accord Healthcare, Inc. Pierre Fabre Medicament GlaxoSmithKline Research & Development Limited	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05615818
NCT05817812	A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients Treated Once Weekly With Efanesoctocog Alfa	Drug: Efanesoctocog alfa	Swedish Orphan Biovitrum Syneos Health	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05817812

해외 바이오의약품 임상 현황 ('23년 5월 5주)

한국바이오의약품협회, 2023.06.07.

○ 프랑스 8건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05733611	RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC	Biological: RP2 Biological: RP3 Biological: atezolizumab Biological: bevacizumab	Replimune Inc. Roche Pharma AG	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05733611
NCT05733598	RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC	Biological: RP3 Biological: atezolizumab Biological: bevacizumab	Replimune Inc. Roche Pharma AG	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05733598
NCT05889572	Safety and Gut Microbiota Analysis of an Oral Microbiotherapy in Patients With Amyotrophic Lateral Sclerosis	Drug: MaaT033	MaaT Pharma	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05889572

○ 독일 7건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05843877	Pancreatic Head Resection or Total Pancreatectomy With Islet Autotransplantation in Patients With Periampullary Cancer and High Risk Profile for the Development of Postoperative Pancreatic Fistula	Biological: Intraportal transplantation of isolated autologous pancreatic islets after total pancreatectomy Procedure: Pancreaticoduodenectomy (classic Whipple or pylorus-preserving)	Technische Universität Dresden KKS Dresden German Cancer Research Center	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05843877
NCT05496192	A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer	Drug: Nivolumab/rHuPH20 Drug: Nivolumab	Bristol-Myers Squibb	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05496192
NCT05533242	Radioimmunotherapy With Lu-177 Labeled 6A10 Fab-fragments in Patients With Glioblastoma After Standard Treatment	Drug: Lu-177 labeled 6A10-Fab-fragments	University Hospital Muenster Isotope Technologies Munich (ITM) Oncologics Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05533242
NCT05817812	A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥ 12 Years Treated Once Weekly With Efanesoctocog Alfa	Drug: Efanesoctocog alfa	Swedish Orphan Biovitrum Syneos Health	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05817812
NCT05733611	RP2/RP3 in Combination With Atezolizumab and Bevacizumab for the Treatment of Patients With CRC	Biological: RP2 Biological: RP3 Biological: atezolizumab Biological: bevacizumab	Replimune Inc. Roche Pharma AG	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05733611
NCT05733598	RP3 in Combination With 1L or 2L Therapy in Patients With Locally Advanced Unresectable or Metastatic HCC	Biological: RP3 Biological: atezolizumab Biological: bevacizumab	Replimune Inc. Roche Pharma AG	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05733598
NCT05880524	Reduction of Systemic Inflammation After Ischemic Stroke by Intravenous DNase Administration (ReSCInD)	Drug: Dornase Alfa Drug: Isotonic Saline Solution	Ludwig-Maximilians - University of Munich University Hospital Erlangen University Hospital Regensburg	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05880524

해외 바이오의약품 임상 현황 ('23년 5월 5주)

한국바이오의약품협회, 2023.06.07.

○ 중국 27건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05882630	Surufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung Cancer	Drug: Surufatinib,Serplulimab,Etoposide,Carboplatin	Fujian Cancer Hospital Hunan Cancer Hospital Wuhan Tongji Hospital	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05882630
NCT05808608	A Study of AK104 Plus Axitinib in Advanced/Metastatic Specific Subtypes of Renal Cell Carcinoma	Drug: AK104 Drug: Axitinib	Hao Zeng West China Hospital	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05808608
NCT05887726	Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors	Drug: Zanubrutinib Drug: Rituximab Drug: Cyclophosphamide Drug: Epirubicin Drug: Vincristine Drug: Prednisone	Liaoning Tumor Hospital & Institute	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05887726
NCT05883176	TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria	Drug: Bevacizumab Biosimilar QL 1101	Sun Yat-sen University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05883176
NCT05881525	NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors	Biological: TC-N201 cells Drug: IL-2 Drug: Fludarabine Drug: Cyclophosphamide Drug: Nab-paclitaxel	TCRCure Biopharma Ltd. Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05881525
NCT05880082	PPIO-004 Clinical Application of Efficacy Prediction Model Based on Epigenomics Sequencing Technology in Neoadjuvant Immunotherapy for Esophageal Cancer	Drug: Tislelizumab	Daping Hospital and the Research Institute of Surgery of the Third Military Medical University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05880082
NCT05868915	HV-101 for Patients With Advanced Solid Tumors	Biological: HV-101	Hervor Therapeutics Renmin Hospital of Wuhan University	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05868915
NCT05865574	A Comparative Pharmacokinetic Study to Evaluate Different Manufacturing Batches of BAT1706 Injection	Drug: BAT1706 Injection	Bio-Thera Solutions	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05865574
NCT05864755	HAIC Combined With Durvalumab, Tremelimumab and Bevacizumab as First-line Therapy in Unresectable Hepatocellular Carcinoma	Drug: HAIC+Durvalumab+Tremelimumab+Bevacizumab	Tianjin Medical University Cancer Institute and Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05864755
NCT05864573	Study of ZGGS15 in Patients With Advanced Solid Tumors	Biological: ZGGS15	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05864573
NCT05859529	A Pharmacokinetic Study of JS002 in Healthy Subjects	Drug: JS002	Shanghai Junshi Bioscience Co., Ltd. Sponsor GmbH	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05859529
NCT05856864	Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy	Drug: Cadonilimab Injection Drug: Ramucirumab Injection	Tianjin Medical University Cancer Institute and Hospital	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05856864
NCT05849246	The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)	Drug: Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed Drug: Sintilimab+Carboplatin or Cisplatin+Pemetrexed Drug: Tusamitamab ravtansine+Sintilimab	Innovent Biologics (Suzhou) Co. Ltd.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05849246
NCT05845723	Tocilizumab and Tofacitinib in the Treatment of Vascular Behçet's Syndrome	Drug: tocilizumab Drug: tofacitinib Drug: cyclophosphamide	Peking Union Medical College Hospital	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05845723

해외 바이오의약품 임상 현황 ('23년 5월 5주)

한국바이오의약품협회, 2023.06.07.

○ 중국 27건

NCT Number	Title	Interventions	Sponsor/Collaborators	Phases	URL
NCT05824481	Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer	Drug: Cadonilimab Drug: Lenvatinib	Sun Yat-sen University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05824481
NCT05824468	Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer	Drug: Zimberelimab Drug: Lenvatinib	Sun Yat-sen University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05824468
NCT05823311	Lenvatinib, Tislelizumab Combined With Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma	Drug: Lenvatinib, tislelizumab, gemcitabine and cisplatin Drug: Gemcitabine and cisplatin	Second Affiliated Hospital, School of Medicine, Zhejiang University The First Affiliated Hospital of Zhengzhou University The Affiliated Tumor Hospital of Xinjiang Medical University	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05823311
NCT05679492	Study on the Safety and Efficacy of Meplazumab for Injection Patients COVID-19	Biological: Meplazumab foe injection Other: Normal saline	Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05679492
NCT05648006	First-line Maintenance of OH2 Injection for Advanced Colorectal Cancer	Biological: OH2 Drug: Capecitabine Drug: Bevacizumab	Binhui Biopharmaceutical Co., Ltd.	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05648006
NCT05400902	HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma	Drug: HAIC Combined with Tislelizumab and Apatinib	Binkui Li Sun Yat-sen University	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05400902
NCT05877001	The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases	Drug: Tislelizumab Drug: Regorafenib Other: HAIC	Peking University Cancer Hospital & Institute	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05877001
NCT04077866	B7-H3 CAR-T for Recurrent or Refractory Glioblastoma	Drug: Temozolomide Biological: B7-H3 CAR-T	Second Affiliated Hospital, School of Medicine, Zhejiang University Ningbo Yinzhou People's Hospital Huizhou Municipal Central Hospital BoYuan RunSheng Pharma (Hangzhou) Co., Ltd.	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT04077866
NCT05498389	EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer	Drug: EMB-01 Drug: Osimertinib	Shanghai EpimAb Biotherapeutics Co., Ltd. Labcorp Corporation of America Holdings, Inc	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05498389
NCT05867563	Clinical Trial Evaluating the Safety of the TQB2103 for Injection	Drug: TQB2103 for injection	Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Phase 1	https://clinicaltrials.gov/ct2/show/study/NCT05867563
NCT05793307	Evaluation of the Safety and Efficacy of Infantile-onset Pompe Disease Gene Therapy Drug	Genetic: GC301	GeneCradle Inc	Phase 1 Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05793307
NCT05890976	Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)	Drug: Semaglutide Drug: Semaglutide Placebo	Novo Nordisk A/S	Phase 3	https://clinicaltrials.gov/ct2/show/study/NCT05890976
NCT05212922	A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC	Drug: YH001 + Toripalimab	Eucre (Beijing) Biopharma Co., Ltd	Phase 2	https://clinicaltrials.gov/ct2/show/study/NCT05212922